Sign in
4

Changes in Ownership

Adaptimmune Therapeutics PLC Filed Acc 0001104659-21-031733

Chief Business Officer acquired 1,785,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
TAYTON-MARTIN HELEN KATRINA Chief Business Officer 2021-03-03 Option exercise +1,785,000 $0.16 $280,245 1,800,000 D
Loading xslF345X03/tm218630-1_4seq1.xml…